Adverse events of anti-tumor necrosis factor α therapy in ankylosing spondylitis

PloS One
Qiang TongDongbao Zhao

Abstract

This study aims to investigate the prevalence of short-term and long-term adverse events associated with tumor necrosis factor-α (TNF-α) blocker treatment in Chinese Han patients suffering from ankylosing spondylitis (AS). The study included 402 Chinese Han AS patients treated with TNF-α blockers. Baseline data was collected. All patients were monitored for adverse events 2 hours following administration. Long-term treatment was evaluated at 8, 12, 52 and 104 weeks follow-up for 172 patients treated with TNF-α blockers. Short-term adverse events occurred in 20.15% (81/402), including rash (3.5%; 14/402), pruritus (1.2%; 5/402), nausea (2.2%; 9/402), headache (0.7%; 3/402), skin allergies (4.0%; 16/402), fever (0.5%; 2/402), palpitations (3.0%; 12/402), dyspnea (0.5%; 2/402), chest pain (0.2%; 1/402), [corrected] abdominal pain (1.0%; 4/402), hypertension (2.2%; 9/402), papilledema (0.5%; 2/402), laryngeal edema (0.2%; 1/402) and premature ventricular contraction (0.2%; 1/402). Long-term adverse events occurred in 59 (34.3%; 59/172) patients, including pneumonia (7.6%; 13/172), urinary tract infections (9.9%; 17/172), otitis media (4.7%; 8/172), tuberculosis are (3.5%; 6/172) [corrected], abscess (1.2%; 2/172), oral candidiasis ...Continue Reading

References

Aug 1, 1995·British Journal of Rheumatology·L G KennedyA Calin
Jul 28, 2006·Arthritis Research & Therapy·Meliha C KapetanovicPierre Geborek
Apr 9, 2010·International Journal of Rheumatic Diseases·Parawee SuwannalaiS Janvitayanujit
May 1, 2008·Expert Review of Clinical Immunology·Andres PeisajovichTerry W Du Clos
Feb 1, 2011·Orvosi hetilap·Gabriella NagyZsuzsánna Károlyi
Feb 3, 2011·The Journal of Rheumatology·Gunnstein BaklandJohannes C Nossent
Mar 2, 2011·The American Journal of the Medical Sciences·Charles F Dillon, Rosemarie Hirsch
Mar 5, 2014·Joint, Bone, Spine : Revue Du Rhumatisme·Dewi GuellecAlain Saraux

❮ Previous
Next ❯

Citations

Dec 23, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Joshua B FrenchHerbert L Bonkovsky
Aug 19, 2016·Expert Opinion on Biological Therapy·Sergio Fernandez-MartinezMd Elvira Casterá
Oct 14, 2016·Scandinavian Journal of Rheumatology·W GunasekeraR Sengupta
Jan 11, 2018·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Michael NurmohamedPaola Accossato

❮ Previous
Next ❯

Methods Mentioned

BETA
ESR

Software Mentioned

SPSS

Related Concepts

Related Feeds

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Babesiosis

Babesiosis is caused by parasites of the genus babesia, which are transmitted in nature by the bite of an infected tick. Discover the latest research on babesiosis here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.